Keeping Track: A Good Week For Interstitial Lung Diseases; Opdivo+Yervoy Gains Liver Cancer Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
The latest news about products accepted into US FDA expedited review programs.
The latest drug development news and highlights from our US FDA Performance Tracker.
The agency tried not to give a marketing advantage to either Boehringer Ingelheim's Ofev or Roche subsidiary InterMune's Esbriet when it simultaneously approved the first two drugs for idiopathic pulmonary fibrosis.